High Growth Tech Stocks To Watch In The United States

In This Article:

The market remained flat over the last week but has risen 27% over the past 12 months, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability, positioning them well in an evolving economic landscape.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

23.83%

24.32%

★★★★★★

Ardelyx

25.47%

69.63%

★★★★★★

Sarepta Therapeutics

23.98%

42.48%

★★★★★★

Alnylam Pharmaceuticals

22.34%

70.30%

★★★★★★

Clene

77.61%

59.19%

★★★★★★

TG Therapeutics

34.86%

56.98%

★★★★★★

Alkami Technology

21.94%

98.60%

★★★★★★

Travere Therapeutics

31.70%

72.51%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 237 stocks from our US High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

TG Therapeutics

Simply Wall St Growth Rating: ★★★★★★

Overview: TG Therapeutics, Inc. is a commercial stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for B-cell mediated diseases globally, with a market cap of approximately $4.60 billion.

Operations: TG Therapeutics focuses on developing and commercializing treatments for B-cell mediated diseases, generating revenue primarily from its biotechnology segment, which accounts for approximately $264.79 million.

TG Therapeutics, despite its current unprofitability, is on a robust upward trajectory with revenue growth forecasted at 34.9% annually, significantly outpacing the US market's 9.1%. The firm's strategic focus on innovative treatments in multiple sclerosis has shown promising long-term efficacy and safety results, particularly with their BRIUMVI product during the ULTIMATE I & II Phase 3 trials. Notably, their recent share repurchase of $2.15 million underscores a commitment to enhancing shareholder value as they edge closer to profitability projected within three years. This blend of aggressive growth strategy and groundbreaking clinical outcomes positions TG Therapeutics as a dynamic player in biotech’s competitive landscape.

NasdaqCM:TGTX Earnings and Revenue Growth as at Dec 2024
NasdaqCM:TGTX Earnings and Revenue Growth as at Dec 2024

AppLovin

Simply Wall St Growth Rating: ★★★★★☆

Overview: AppLovin Corporation operates a software-based platform designed to assist advertisers in optimizing the marketing and monetization of their content globally, with a market capitalization of $108.89 billion.